Is RAD-140 bad for kidneys? No published study shows RAD-140, a selective androgen receptor modulator, damaging kidney tissue directly. The one acute kidney injury on record arrived at the end of a severe drug-induced liver injury, and the only human trial, in women with breast cancer, recorded raised liver enzymes, markers of liver cell injury, with vomiting and dehydration.
The same trial recorded a rise in prostate-specific antigen (PSA), a protein that prostate tissue makes under androgen stimulation, and that is the whole of the prostate record. The published cases place the harm in liver tissue first. The joint pain and stomach upsets attached to the compound come from descriptions outside the published trials, and those descriptions record symptoms, not their causes.
Why would one compound touch so many organs? RAD 140 is an orally active, experimental compound of the class of selective androgen receptor modulators, or SARMs, and the RAD 140 mechanism of action rests on tissue-selective effects at the androgen receptor, a protein inside cells that androgens switch on; androgen receptors sit in the kidney, the prostate and the gut alike. The human record on organ safety is nonetheless thin, because that trial is the only human study of the compound and it enrolled women with advanced breast cancer. The RAD 140 side effects recorded in the trial and in the published cases reach other organ systems, the liver first among them, and the parent article covers them.
The sections below take the organs in turn, kidney function, prostate tissue, the gastrointestinal tract, the joints and headache, and set what the trial, the published cases and the laboratory studies measured beside what is described outside the trials. The detail of drug-induced liver injury, the cardiac effects, the hormonal changes and mood have their own pages.
What the human trial recorded for the gut and kidneys
Vomiting, dehydration, decreased appetite and weight loss each turned up in the same share of participants in the only human trial of the compound, as the chart shows, and three of the four describe a loss of fluid and nutrition, which is where they bear on the kidneys. The events arose in a first-in-human phase 1 trial, which enrolled 22 heavily pretreated postmenopausal women with metastatic breast cancer, negative for HER2 and positive for the receptor for oestrogen, chiefly oestradiol; 21 of them had androgen receptor-positive disease.
[Figure 1. Adverse events in RAD140’s phase 1 trial. Share of the 22 women with advanced breast cancer in RAD140’s only human trial who had each event at any grade, with doses of 50 to 150 mg pooled. Raised liver enzymes outnumbered the gut and fluid events; the proportions describe this group, not healthy men.]
No single dose level accounts for those gastrointestinal events, because the study escalated through 50 mg, 100 mg and 150 mg once daily and set 100 mg as the maximum tolerated dose, the highest level administered without unacceptable toxicity. The elimination half-life came out at 44.7 hours, long enough to support once-daily administration.
Markers of liver injury outran every gastrointestinal event in that trial, a record that belongs with the RAD-140 studies rather than with the kidneys.
Set against the kidney question, the trial offers dehydration among its frequent events and hypophosphataemia among its severe ones, and nothing more: the record names neither acute kidney injury nor a fall in glomerular filtration rate. The participants were heavily pretreated women with advanced cancer, so these proportions describe that population, not healthy men.
What the trial’s PSA readings say about the prostate
In the RAD140 trial, prostate-specific antigen rose in most of the participants tested for it, and concentrations of sex hormone-binding globulin (SHBG), the blood protein that carries sex hormones and limits the fraction free to act, fell in every participant tested; the chart below gives the counts. The investigators treated the two as surrogate markers, measurements that stand in for an effect not observed directly, in this case engagement of the androgen receptor rather than any benefit to a patient. Because the two markers moved in opposite directions, each reading supports the other. Neither was collected to describe prostate tissue.
[Figure 2. PSA and SHBG responses in the trial. Of the 22 women enrolled, 20 were tested for PSA and 18 for SHBG. SHBG fell in all 18 and PSA rose in 16 of 20. Both served as markers of androgen receptor engagement in women, not as measurements of prostate tissue.]
The PSA response was also discordant. Four of the participants tested showed no rise at all across an escalation that reached the maximum tolerated dose, so the marker did not respond uniformly even in so small a cohort, and the investigators did not measure either marker in everyone enrolled: two participants contributed no PSA reading and four no SHBG reading.
For the RAD140 prostate question the limit is sharper than the counts suggest. Clinicians read a PSA concentration in men against age-specific reference ranges, prostate volume and its rate of change over time, and none of that framework applied here, because every participant was a postmenopausal woman. The trial measured neither prostate volume, nor urinary flow rate, nor any endpoint of disease in the gland. What it establishes is that testolone engages the androgen receptor in humans, as an androgen-responsive marker shows, and it leaves the gland itself unexamined.
Acute kidney injury in the case reports
The one acute kidney injury recorded with RAD140 came at the end of a hepatic illness, not at its onset. A previously healthy young man developed severe cholestatic drug-induced liver injury, injury to liver tissue caused by a drug or supplement, after exposure to a supplement containing RAD-140 and the earlier selective androgen receptor modulator andarine (S-4). When bile flow within liver tissue is impaired, which is what cholestatic injury means, bile pigments build up in the blood, and that pattern dominates the published evidence on RAD140 and the liver. His serum bilirubin kept rising after the product was withdrawn and corticosteroids were given, so he needed plasmapheresis, in which blood plasma is removed and replaced. From there his course ran on to inflammation of the pancreas, known as pancreatitis, and to acute kidney injury requiring intensive care.
In that sequence the kidneys failed only once the cholestatic liver injury had failed to resolve despite two treatments, in a patient critically ill with pancreatitis. The published report gives no creatinine value, no urine output and no duration of the acute kidney injury, so its severity cannot be graded. So the case shows acute kidney injury arising in the course of RAD-140-associated drug-induced liver injury; it does not show the compound acting on kidney tissue. The authors attribute the liver injury to RAD-140 and call it the most severe RAD-140-associated case reported to date.
One finding in these cases is often taken for kidney injury and is not. A young man exposed to RAD-140 for 16 weeks, one of the cases in the table below, presented with dark urine, pale stools and jaundice, the yellowing of skin and eyes from raised bilirubin, and the authors tied all three to cholestatic liver injury. Dark urine of that kind goes with raised bilirubin and says nothing about the kidneys.
LiverTox, the National Institutes of Health reference work on drug-induced liver injury, associates selective androgen receptor modulators as a class with cholestatic liver injury, and the single recorded acute kidney injury developed from that pattern. No published case here describes kidney injury in a patient whose liver tissue was spared.
Five published RAD-140 cases side by side
Patient
Products named
Presenting features
Course after the product stopped
Kidney finding
26-year-old man
RAD140
Nausea, vomiting, severe right upper quadrant pain, jaundice
Liver function panel normal at 2-month follow-up
None reported
22-year-old man
RAD-140
Jaundice, nausea, fatigue, itching, dark urine, pale stools
Total bilirubin fell from 530 to 188 µmol/L at one month; enzymes normal 3 to 12 months after stopping
Dark urine with raised bilirubin; no kidney injury reported
24-year-old man
RAD-140
Diffuse abdominal pain, jaundice, itching
Peak total bilirubin 38.5 mg/dL; symptoms and injury resolved after stopping
None reported
Previously healthy young man
RAD-140 and andarine (S-4)
Severe cholestatic liver injury
Bilirubin kept rising despite stopping and corticosteroids; plasmapheresis, pancreatitis
Acute kidney injury requiring intensive care
54-year-old man
RAD-140 and MK-677
Left upper quadrant pain and vomiting from splenic rupture
Embolisation, then total splenectomy; authors call the compounds’ role speculative
None reported
Lower back and kidney-area pain described in discussions
In descriptions beyond the trials, lower back and flank pain ranks among the complaints most often attached to RAD-140, and the accounts usually frame it as a worry that the pain comes from the kidneys rather than as an observation. They describe the following:
a vague deep ache to one side of the spine
pain across the lower back and coccyx
stiffness through the back
painful tightness of the back musculature that builds during physical exertion and eases afterwards
Outside the trial record, back pain is hard to separate from a pre-existing complaint. One account describes pain that worsened during exposure in someone with a family history of the same condition, a combination that leaves the cause open, and another describes palpation of both sides of the lower back as a check for kidney disease, a manoeuvre that can neither establish nor exclude it.
Among the effects described outside the trials, this pain is sometimes called kidney pain outright, with no blood test, no urine test and no imaging behind the label. Such descriptions record where a sensation was felt and nothing of its origin, which sets them apart from the measured findings of the trial and the case reports.
Nausea, vomiting and stomach pain in the case reports
In the RAD140 case reports, nausea, vomiting and abdominal pain appear not as effects on the gastrointestinal tract itself but as the presenting features of drug-induced liver injury. One report concerns a 26-year-old man whose nausea, vomiting, severe right upper quadrant abdominal pain and jaundice came from acute drug-induced liver injury, and whose extensive inpatient work-up found no cause other than the SARM RAD140.
The 22-year-old man with the dark urine presented the same way, with nausea, fatigue and pruritus (itching) alongside the jaundice, and a third case describes two weeks of diffuse abdominal pain with jaundice in a 24-year-old man after five weeks of exposure to RAD-140. Only in the most severe case was a second organ itself inflamed, when pancreatitis complicated the abdominal picture.
One further case with abdominal symptoms falls outside the hepatic pattern. A 54-year-old man presented with acute left upper quadrant abdominal pain and vomiting from a spontaneous splenic rupture, in which the spleen tears without preceding trauma, after recent exposure to RAD-140 and to the growth hormone secretagogue MK-677 (ibutamoren). Splenic artery embolisation, which deliberately blocks that artery to control the bleeding, stabilised him only briefly, and total splenectomy followed. Histopathological examination of the spleen showed large areas of splenic infarction, with features raising the possibility of an underlying vascular malformation, and the authors call the role of the two compounds speculative. The qualification matters: the case records a temporal association, not a demonstrated cause.
We explore the potential and speculative role of performance-enhancing compounds in precipitating splenic complications
Outside the trial record, gastrointestinal upset is one of the earlier complaints to arise during exposure to RAD-140, and the severity described ranges widely, from repeated vomiting in some accounts to sharp abdominal pain and a general nausea in others. None of these accounts records jaundice or a test result.
Beyond the trial data, abdominal discomfort is also described at a fixed site: a heaviness or mild pain in the right upper quadrant of the abdomen, below the ribs, most marked on walking. A few accounts place pain over the left ribs, together with lethargy, and one describes a slight abdominal bloating, attributed to a second compound rather than to RAD-140. These descriptions record symptoms and nothing more, since no measurement stands behind any of them and none was followed through to a diagnosis.
Why does RAD-140 cause joint pain?
Accounts outside the published studies describe joint pain with RAD-140 as a dry or creaky ache, and they explain it either by a general drying effect of the compound or by a fall in oestrogen, chiefly in oestradiol, the main oestrogen in men and a product of testosterone. Neither explanation rests on a measurement, so the descriptions fix where and when the ache is felt but not its cause.
In those accounts the joints cluster in the upper body: elbows and wrists come up most often, followed by shoulders and by fingers and hands that are stiff on waking, and the arch of the foot is named as well. The joints hurt under heavy load and ease at rest, and the ache tends to arrive after several weeks of exposure rather than in the first days. In a number of accounts a second compound was present at the same time, so the attribution to RAD-140 stays unsettled.
The same accounts do not all run one way. A number describe joints that felt unchanged or better during exposure, and a few describe no joint complaint at all. RAD-140 is also described, outside the trial record, as harder on the joints than ostarine, also called MK-2866, another selective androgen receptor modulator that several accounts call easier on painful joints. The spread within these RAD-140 reports on Reddit and other discussions is the main finding: the complaint is common enough to be widely described, yet too inconsistent to form a single pattern.
Does RAD-140 dry out the joints?
Among the effects described outside the trials, the one most consistently attached to RAD-140 is a drying quality, which many accounts extend to joints they call dry, creaky or stiff. The compound is widely described as a dry compound, and the accounts then use that description to explain the joint discomfort. Other accounts describe joints that felt normal several weeks into exposure, so the link between the dryness and the joints is not uniform.
Outside the trial record, dryness is also placed at sites other than the joints, and because fluid and salts so often come up alongside it, those accounts read it as a matter of fluid balance rather than of the joints themselves. The sites they name are these:
dry skin, in several accounts
dry hands, in several accounts
a general feeling of dehydration, described alongside them
dry eyes, in one account
a dry mouth, in that same account
a gum problem, in that same account
In descriptions beyond the trials, the drying quality of RAD-140 is itself contested. Many accounts describe no fluid retention and a dry, hard appearance, a smaller number describe fluid retention during exposure, and both descriptions sit in the same material. Nothing in either measures the cartilage or the synovial fluid that lubricates the joints.
Tendon and ligament strain described in discussions
Outside the published studies, tendons and ligaments are described as a site of strain separate from the joints themselves, with tightness the recurring term: tight tendons during exposure, strain of the elbow ligaments, and forearm pain resembling lateral epicondylitis (tennis elbow). One account also describes tendon tears in the arm during arm wrestling.
In descriptions beyond the trials, a stronger claim passes second hand, that RAD-140 tightens tendons to the point of rupture. It cannot be weighed, because it appears as something heard rather than observed and because nothing in such accounts measures tendon tissue.
In those accounts the opposite appears too: some ask whether RAD-140 might ease tendinitis, inflammation of a tendon, and one describes a tendinitis that cleared during exposure but judges it likely to have healed on its own. Injury and recovery descriptions alike rest on single observations, with no imaging and no follow-up behind them.
Is low oestrogen the cause of joint pain on RAD-140?
Low oestrogen is generally held to be one plausible contributor to joint discomfort in men, but it is not an established cause of the ache described with RAD-140. Oestradiol protects the joints, and falls in oestradiol go with pain in them and reduced well-being where endogenous androgen production is suppressed or its conversion to oestrogen is inhibited.
Selective androgen receptor modulators suppress endogenous testosterone production, and because they are not themselves converted to oestradiol, they also reduce the testosterone available for that conversion. A fall in oestradiol is therefore a reasonable expectation on general grounds, as a rule, but it remains an inference from androgen pharmacology rather than a measured finding for this compound.
Why does RAD-140 cause headaches?
Outside the trial record, headache turns up again and again during exposure to RAD-140, usually as a daily headache or a mild one that lingers after training. Nothing established ties the compound to it: headache is generally held to be a non-specific effect of androgenic compounds as a class, and it has never been characterised as an effect of RAD-140 in its own right. The accounts blame the following:
rises in blood pressure
increases in haematocrit and red cell mass
shifts in fluid balance
shifts in electrolytes, the dissolved salts such as sodium and potassium that govern fluid distribution and skeletal muscle contraction
Beyond the trial data, a lingering headache is described together with poor sleep and a tight chest at night, and that combination is the one most often raised as a concern; the headaches come up repeatedly as persistent, which points to a lasting rather than a passing effect. Selective androgen receptor modulators are also widely understood to suppress endogenous testosterone production and to alter blood lipids, and those hormonal and cardiovascular changes are often named as possible contributors to headache and disturbed sleep. A persistent headache alongside chest tightness is treated in the clinical literature as a sign warranting medical assessment, not as an expected effect.
Why do some people feel dizzy on RAD-140?
Beyond the trial data, dizziness during exposure to RAD-140 is described most often as a matter of blood glucose, because it tends to arise together with hunger and tiredness rather than on its own, and all three sensations are placed chiefly in the hours around physical exertion.
Among the effects described outside the trials, marked dizziness and lethargy appear in one account after exposure had ended, again attributed to blood glucose, and a second account records a vivid episode of near loss of consciousness, which a medical assessment attributed to a very low blood glucose concentration. Neither account records a blood glucose measurement made during exposure, so the attribution stands as an interpretation offered after the event.
Can RAD-140 cause muscle cramps, rashes or chest tightness?
Outside the published studies, skeletal muscle cramps, skin rashes and chest tightness are all described as arising during exposure to RAD-140. The cramps and the tightness are commonly put down to dehydration and to depletion of electrolytes, the dissolved salts such as sodium and potassium that govern fluid distribution and skeletal muscle contraction, rather than to a direct action of the compound on muscle tissue. The cramping itself is described as severe and painful, in the calves and shins, the biceps and the back during physical exertion.
Outside the trial record, skin findings appear in fewer accounts: a red rash across the upper thighs, reddened knuckles and markedly dry skin. Chest tightness is described as arising during exposure, sometimes on lying down to sleep, together with an abnormal sensation and pain on the left side, and one account attributes that pain directly to dehydration and electrolyte depletion rather than to any action of RAD140 on the heart.
In descriptions beyond the trials, two further complaints appear alongside these: profuse sweating and numbness in one leg. The electrolyte explanation offered within such accounts remains an interpretation, because none of them rests on a measurement of serum electrolytes, of blood pressure or of skin pathology.
Dose and length of exposure in the trial and the case reports
The trial administered 50 mg, 100 mg or 150 mg once daily and set 100 mg as the maximum tolerated dose. The published cases describe drug-induced liver injury after five weeks of exposure and again after 16 weeks. That structure of RAD140 doses says little about how harm relates to dose: the trial recorded severe events across the escalation, and it set the maximum tolerated dose at 100 mg because the level above it could not be sustained.
The cases complicate any reading by dose further. The injury in the 26-year-old man was characterised as idiosyncratic drug-induced liver injury, an unpredictable reaction that does not follow dose or duration the way a directly toxic effect would, so a low exposure cannot be read as a safe one. Neither the five-week nor the 16-week exposure came with any analysis of the product involved, which leaves the quantity actually reaching each patient unknown; the length of exposure is the only dimension these cases fix.
Novel selective androgen receptor modulators such as RAD140 may be associated with idiosyncratic drug-induced liver injury.
What the case reports recorded after exposure ended
In most of the published cases the drug-induced liver injury eased once exposure to the product ended. The 26-year-old man had a normalised liver function panel and no recurrence of symptoms at two-month follow-up. In the 22-year-old man, total bilirubin fell from a peak of 530 µmol/L to 188 µmol/L at one month, and the reviewing authors report liver enzymes normalising three to twelve months after the product was withdrawn. The 24-year-old man followed the same course: his total bilirubin peaked at 38.5 mg/dL, and both his symptoms and the drug-induced liver injury resolved after cessation of the agent.
[Figure 3. Bilirubin over 35 days in one case. Total and direct bilirubin, in mg/dL, in one 22-year-old man with cholestatic liver injury after 16 weeks of a RAD-140 product. Bilirubin peaked near day 14 and was still well above normal at day 35; his enzymes took three to twelve months to normalise.]
The severe case broke the pattern. There, bilirubin went on rising despite withdrawal of the product and corticosteroid therapy, and the course ran on to plasmapheresis, pancreatitis and acute kidney injury. The contrast between the two courses is the most useful finding this small series offers on the kidneys: acute kidney injury appeared only where the drug-induced liver injury itself failed to settle after exposure ended.
What the products in the case reports contained
RAD-140 was not the only compound present in some of these reports. The supplement in the severe case also held andarine, and the splenic case followed recent exposure to MK-677 alongside RAD-140. No case in which two compounds were present can assign the injury to one of them, and the authors of the splenic case say as much when they call the contribution of either compound speculative.
Product labels are no more reliable. Australia’s Therapeutic Goods Administration (TGA) found, on testing unapproved SARM products, that they were significantly under-dosed: the packages named more than analysis found inside. None of the published cases reports an independent analysis of the product involved, a gap that leaves both the identity and the amount of each exposure uncertain. Laboratory work can do without that uncertainty, which is why the RAD-140 for sale in our shop comes with batch and purity data, as do the other SARMs for sale we supply in the UK for research.
RAD140 and the prostate in cell and animal studies
In prostate carcinoma cells grown in culture, RAD-140 showed androgenic activity in an androgen-responsive reporter gene assay, which couples a measurable signal to activation of the receptor under study. The same compounds produced weaker androgenic effects in a yeast androgen screen engineered to respond to androgen receptor ligands than in the prostate cells: the comparator compound GSK-2881078 gave a half-maximal effective concentration of 4.44 × 10⁻⁶ M in the yeast screen against 3.99 × 10⁻⁹ M in the prostate cells. When the three compounds were modelled in the ligand binding domain of the androgen receptor, slight differences in their binding modes appeared.
The animal work is older and answers a different question: the design and synthesis paper for RAD140 reported its potency and its oral bioavailability, the fraction of an orally administered dose that reaches the circulation intact, tested RAD140 in rats and monkeys across several preclinical models of anabolic androgen action, and reported binding affinities of 7 against 29 nM. Activity at an androgen-responsive gene in cultured prostate cells cannot stand as a statement about human prostate tissue, because neither the cell systems nor the animal models measured prostate volume, urinary symptoms or disease of the gland over time.
Limits of the evidence on kidneys, prostate and gut
The evidence on whether RAD-140 is bad for the kidneys, the prostate or the gut is thin in ways that bear on each organ question. Its event proportions come from 22 heavily pretreated women with advanced breast cancer and cannot be carried across to healthy men, and its PSA and SHBG movements were markers of receptor engagement, not prostate outcomes. Each published case beyond the trial describes a single patient, which establishes that an injury followed exposure but not how often such injuries occur.
Two further limits weaken the attribution of each injury to the compound. Some cases involved a second compound alongside RAD-140, and in the splenic rupture case the authors themselves judged the link speculative and found features raising the possibility of an underlying vascular malformation. The products are the other limit: no case included an analysis of the product involved, so the identity and quantity of each exposure remain unknown.
[Figure 4. RAD140’s published record, 2011 to 2026. Primary sources cited in this article, by year published: a design paper in rats and monkeys, a cell study, one trial in 22 women with metastatic breast cancer and five single-patient case reports. Each mark is a paper, not an incidence.]
Joint pain, dry joints, tendon and ligament strain, headaches, dizziness, skeletal muscle cramps, rashes, chest tightness, lower back and kidney-area pain, and stomach upsets are described only outside the published trials and case reports, and no published study among this article’s sources has measured them.
No regulator has approved RAD140 for clinical use, and selective androgen receptor modulators stand on the WADA prohibited list for their myoanabolic effects.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In the one published case of acute kidney injury linked to RAD-140, how did the kidney injury arise?
As a direct toxic effect on kidney tissue from the start
Late, in a liver injury that kept worsening after withdrawal ✓
Early, as the first sign before any liver changes were seen
From dehydration alone, while liver tests stayed within normal range
The kidney injury came only after a severe cholestatic liver injury kept worsening despite withdrawal of the product and corticosteroids, alongside pancreatitis.
What did the rise in prostate-specific antigen (PSA) in the only human trial of RAD140 show?
That prostate tissue enlarged in most of the participants
That the compound carries a measured risk of prostate cancer
That the compound engaged the androgen receptor in humans ✓
That the prostate is spared by its tissue selectivity
The trial enrolled only postmenopausal women and used PSA and SHBG as markers of androgen receptor engagement, measuring no prostate endpoint.
In the 54-year-old man whose spleen ruptured, how did the authors judge the role of RAD-140?
As proven, since no other cause was found on examination
As a known effect, long established for the compound class
As unrelated, the rupture being traced to an injury
As speculative, with signs of a possible vascular malformation ✓
The spleen showed features raising the possibility of an underlying vascular malformation, and the authors called the role of RAD-140 and MK-677 speculative.
In the published case reports, what were the nausea, vomiting and abdominal pain most often a sign of?
Drug-induced liver injury showing its first features ✓
A direct irritant effect of the compound on the gut
Dehydration and electrolyte loss during physical exertion
Inflammation of the pancreas present from the start
A 26-year-old man presented with nausea, vomiting, right upper quadrant pain and jaundice from acute drug-induced liver injury, with no other cause found.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Is RAD-140 bad for kidneys? What the case reports show
By Ailsa Gemmell · Reviewed by Laura Walker, PhD
Published · Updated · 24 min read
The short answer on kidneys, prostate and gut
Is RAD-140 bad for kidneys? No published study shows RAD-140, a selective androgen receptor modulator, damaging kidney tissue directly. The one acute kidney injury on record arrived at the end of a severe drug-induced liver injury, and the only human trial, in women with breast cancer, recorded raised liver enzymes, markers of liver cell injury, with vomiting and dehydration.
The same trial recorded a rise in prostate-specific antigen (PSA), a protein that prostate tissue makes under androgen stimulation, and that is the whole of the prostate record. The published cases place the harm in liver tissue first. The joint pain and stomach upsets attached to the compound come from descriptions outside the published trials, and those descriptions record symptoms, not their causes.
Why would one compound touch so many organs? RAD 140 is an orally active, experimental compound of the class of selective androgen receptor modulators, or SARMs, and the RAD 140 mechanism of action rests on tissue-selective effects at the androgen receptor, a protein inside cells that androgens switch on; androgen receptors sit in the kidney, the prostate and the gut alike. The human record on organ safety is nonetheless thin, because that trial is the only human study of the compound and it enrolled women with advanced breast cancer. The RAD 140 side effects recorded in the trial and in the published cases reach other organ systems, the liver first among them, and the parent article covers them.
The sections below take the organs in turn, kidney function, prostate tissue, the gastrointestinal tract, the joints and headache, and set what the trial, the published cases and the laboratory studies measured beside what is described outside the trials. The detail of drug-induced liver injury, the cardiac effects, the hormonal changes and mood have their own pages.
What the human trial recorded for the gut and kidneys
Vomiting, dehydration, decreased appetite and weight loss each turned up in the same share of participants in the only human trial of the compound, as the chart shows, and three of the four describe a loss of fluid and nutrition, which is where they bear on the kidneys. The events arose in a first-in-human phase 1 trial, which enrolled 22 heavily pretreated postmenopausal women with metastatic breast cancer, negative for HER2 and positive for the receptor for oestrogen, chiefly oestradiol; 21 of them had androgen receptor-positive disease.
No single dose level accounts for those gastrointestinal events, because the study escalated through 50 mg, 100 mg and 150 mg once daily and set 100 mg as the maximum tolerated dose, the highest level administered without unacceptable toxicity. The elimination half-life came out at 44.7 hours, long enough to support once-daily administration.
Markers of liver injury outran every gastrointestinal event in that trial, a record that belongs with the RAD-140 studies rather than with the kidneys.
Set against the kidney question, the trial offers dehydration among its frequent events and hypophosphataemia among its severe ones, and nothing more: the record names neither acute kidney injury nor a fall in glomerular filtration rate. The participants were heavily pretreated women with advanced cancer, so these proportions describe that population, not healthy men.
What the trial’s PSA readings say about the prostate
In the RAD140 trial, prostate-specific antigen rose in most of the participants tested for it, and concentrations of sex hormone-binding globulin (SHBG), the blood protein that carries sex hormones and limits the fraction free to act, fell in every participant tested; the chart below gives the counts. The investigators treated the two as surrogate markers, measurements that stand in for an effect not observed directly, in this case engagement of the androgen receptor rather than any benefit to a patient. Because the two markers moved in opposite directions, each reading supports the other. Neither was collected to describe prostate tissue.
The PSA response was also discordant. Four of the participants tested showed no rise at all across an escalation that reached the maximum tolerated dose, so the marker did not respond uniformly even in so small a cohort, and the investigators did not measure either marker in everyone enrolled: two participants contributed no PSA reading and four no SHBG reading.
For the RAD140 prostate question the limit is sharper than the counts suggest. Clinicians read a PSA concentration in men against age-specific reference ranges, prostate volume and its rate of change over time, and none of that framework applied here, because every participant was a postmenopausal woman. The trial measured neither prostate volume, nor urinary flow rate, nor any endpoint of disease in the gland. What it establishes is that testolone engages the androgen receptor in humans, as an androgen-responsive marker shows, and it leaves the gland itself unexamined.
Acute kidney injury in the case reports
The one acute kidney injury recorded with RAD140 came at the end of a hepatic illness, not at its onset. A previously healthy young man developed severe cholestatic drug-induced liver injury, injury to liver tissue caused by a drug or supplement, after exposure to a supplement containing RAD-140 and the earlier selective androgen receptor modulator andarine (S-4). When bile flow within liver tissue is impaired, which is what cholestatic injury means, bile pigments build up in the blood, and that pattern dominates the published evidence on RAD140 and the liver. His serum bilirubin kept rising after the product was withdrawn and corticosteroids were given, so he needed plasmapheresis, in which blood plasma is removed and replaced. From there his course ran on to inflammation of the pancreas, known as pancreatitis, and to acute kidney injury requiring intensive care.
In that sequence the kidneys failed only once the cholestatic liver injury had failed to resolve despite two treatments, in a patient critically ill with pancreatitis. The published report gives no creatinine value, no urine output and no duration of the acute kidney injury, so its severity cannot be graded. So the case shows acute kidney injury arising in the course of RAD-140-associated drug-induced liver injury; it does not show the compound acting on kidney tissue. The authors attribute the liver injury to RAD-140 and call it the most severe RAD-140-associated case reported to date.
One finding in these cases is often taken for kidney injury and is not. A young man exposed to RAD-140 for 16 weeks, one of the cases in the table below, presented with dark urine, pale stools and jaundice, the yellowing of skin and eyes from raised bilirubin, and the authors tied all three to cholestatic liver injury. Dark urine of that kind goes with raised bilirubin and says nothing about the kidneys.
LiverTox, the National Institutes of Health reference work on drug-induced liver injury, associates selective androgen receptor modulators as a class with cholestatic liver injury, and the single recorded acute kidney injury developed from that pattern. No published case here describes kidney injury in a patient whose liver tissue was spared.
Five published RAD-140 cases side by side
Lower back and kidney-area pain described in discussions
In descriptions beyond the trials, lower back and flank pain ranks among the complaints most often attached to RAD-140, and the accounts usually frame it as a worry that the pain comes from the kidneys rather than as an observation. They describe the following:
Outside the trial record, back pain is hard to separate from a pre-existing complaint. One account describes pain that worsened during exposure in someone with a family history of the same condition, a combination that leaves the cause open, and another describes palpation of both sides of the lower back as a check for kidney disease, a manoeuvre that can neither establish nor exclude it.
Among the effects described outside the trials, this pain is sometimes called kidney pain outright, with no blood test, no urine test and no imaging behind the label. Such descriptions record where a sensation was felt and nothing of its origin, which sets them apart from the measured findings of the trial and the case reports.
Nausea, vomiting and stomach pain in the case reports
In the RAD140 case reports, nausea, vomiting and abdominal pain appear not as effects on the gastrointestinal tract itself but as the presenting features of drug-induced liver injury. One report concerns a 26-year-old man whose nausea, vomiting, severe right upper quadrant abdominal pain and jaundice came from acute drug-induced liver injury, and whose extensive inpatient work-up found no cause other than the SARM RAD140.
The 22-year-old man with the dark urine presented the same way, with nausea, fatigue and pruritus (itching) alongside the jaundice, and a third case describes two weeks of diffuse abdominal pain with jaundice in a 24-year-old man after five weeks of exposure to RAD-140. Only in the most severe case was a second organ itself inflamed, when pancreatitis complicated the abdominal picture.
One further case with abdominal symptoms falls outside the hepatic pattern. A 54-year-old man presented with acute left upper quadrant abdominal pain and vomiting from a spontaneous splenic rupture, in which the spleen tears without preceding trauma, after recent exposure to RAD-140 and to the growth hormone secretagogue MK-677 (ibutamoren). Splenic artery embolisation, which deliberately blocks that artery to control the bleeding, stabilised him only briefly, and total splenectomy followed. Histopathological examination of the spleen showed large areas of splenic infarction, with features raising the possibility of an underlying vascular malformation, and the authors call the role of the two compounds speculative. The qualification matters: the case records a temporal association, not a demonstrated cause.
Stomach upsets described in discussions
Outside the trial record, gastrointestinal upset is one of the earlier complaints to arise during exposure to RAD-140, and the severity described ranges widely, from repeated vomiting in some accounts to sharp abdominal pain and a general nausea in others. None of these accounts records jaundice or a test result.
Beyond the trial data, abdominal discomfort is also described at a fixed site: a heaviness or mild pain in the right upper quadrant of the abdomen, below the ribs, most marked on walking. A few accounts place pain over the left ribs, together with lethargy, and one describes a slight abdominal bloating, attributed to a second compound rather than to RAD-140. These descriptions record symptoms and nothing more, since no measurement stands behind any of them and none was followed through to a diagnosis.
Why does RAD-140 cause joint pain?
Accounts outside the published studies describe joint pain with RAD-140 as a dry or creaky ache, and they explain it either by a general drying effect of the compound or by a fall in oestrogen, chiefly in oestradiol, the main oestrogen in men and a product of testosterone. Neither explanation rests on a measurement, so the descriptions fix where and when the ache is felt but not its cause.
In those accounts the joints cluster in the upper body: elbows and wrists come up most often, followed by shoulders and by fingers and hands that are stiff on waking, and the arch of the foot is named as well. The joints hurt under heavy load and ease at rest, and the ache tends to arrive after several weeks of exposure rather than in the first days. In a number of accounts a second compound was present at the same time, so the attribution to RAD-140 stays unsettled.
The same accounts do not all run one way. A number describe joints that felt unchanged or better during exposure, and a few describe no joint complaint at all. RAD-140 is also described, outside the trial record, as harder on the joints than ostarine, also called MK-2866, another selective androgen receptor modulator that several accounts call easier on painful joints. The spread within these RAD-140 reports on Reddit and other discussions is the main finding: the complaint is common enough to be widely described, yet too inconsistent to form a single pattern.
Does RAD-140 dry out the joints?
Among the effects described outside the trials, the one most consistently attached to RAD-140 is a drying quality, which many accounts extend to joints they call dry, creaky or stiff. The compound is widely described as a dry compound, and the accounts then use that description to explain the joint discomfort. Other accounts describe joints that felt normal several weeks into exposure, so the link between the dryness and the joints is not uniform.
Outside the trial record, dryness is also placed at sites other than the joints, and because fluid and salts so often come up alongside it, those accounts read it as a matter of fluid balance rather than of the joints themselves. The sites they name are these:
In descriptions beyond the trials, the drying quality of RAD-140 is itself contested. Many accounts describe no fluid retention and a dry, hard appearance, a smaller number describe fluid retention during exposure, and both descriptions sit in the same material. Nothing in either measures the cartilage or the synovial fluid that lubricates the joints.
Tendon and ligament strain described in discussions
Outside the published studies, tendons and ligaments are described as a site of strain separate from the joints themselves, with tightness the recurring term: tight tendons during exposure, strain of the elbow ligaments, and forearm pain resembling lateral epicondylitis (tennis elbow). One account also describes tendon tears in the arm during arm wrestling.
In descriptions beyond the trials, a stronger claim passes second hand, that RAD-140 tightens tendons to the point of rupture. It cannot be weighed, because it appears as something heard rather than observed and because nothing in such accounts measures tendon tissue.
In those accounts the opposite appears too: some ask whether RAD-140 might ease tendinitis, inflammation of a tendon, and one describes a tendinitis that cleared during exposure but judges it likely to have healed on its own. Injury and recovery descriptions alike rest on single observations, with no imaging and no follow-up behind them.
Is low oestrogen the cause of joint pain on RAD-140?
Low oestrogen is generally held to be one plausible contributor to joint discomfort in men, but it is not an established cause of the ache described with RAD-140. Oestradiol protects the joints, and falls in oestradiol go with pain in them and reduced well-being where endogenous androgen production is suppressed or its conversion to oestrogen is inhibited.
Selective androgen receptor modulators suppress endogenous testosterone production, and because they are not themselves converted to oestradiol, they also reduce the testosterone available for that conversion. A fall in oestradiol is therefore a reasonable expectation on general grounds, as a rule, but it remains an inference from androgen pharmacology rather than a measured finding for this compound.
Why does RAD-140 cause headaches?
Outside the trial record, headache turns up again and again during exposure to RAD-140, usually as a daily headache or a mild one that lingers after training. Nothing established ties the compound to it: headache is generally held to be a non-specific effect of androgenic compounds as a class, and it has never been characterised as an effect of RAD-140 in its own right. The accounts blame the following:
Beyond the trial data, a lingering headache is described together with poor sleep and a tight chest at night, and that combination is the one most often raised as a concern; the headaches come up repeatedly as persistent, which points to a lasting rather than a passing effect. Selective androgen receptor modulators are also widely understood to suppress endogenous testosterone production and to alter blood lipids, and those hormonal and cardiovascular changes are often named as possible contributors to headache and disturbed sleep. A persistent headache alongside chest tightness is treated in the clinical literature as a sign warranting medical assessment, not as an expected effect.
Why do some people feel dizzy on RAD-140?
Beyond the trial data, dizziness during exposure to RAD-140 is described most often as a matter of blood glucose, because it tends to arise together with hunger and tiredness rather than on its own, and all three sensations are placed chiefly in the hours around physical exertion.
Among the effects described outside the trials, marked dizziness and lethargy appear in one account after exposure had ended, again attributed to blood glucose, and a second account records a vivid episode of near loss of consciousness, which a medical assessment attributed to a very low blood glucose concentration. Neither account records a blood glucose measurement made during exposure, so the attribution stands as an interpretation offered after the event.
Can RAD-140 cause muscle cramps, rashes or chest tightness?
Outside the published studies, skeletal muscle cramps, skin rashes and chest tightness are all described as arising during exposure to RAD-140. The cramps and the tightness are commonly put down to dehydration and to depletion of electrolytes, the dissolved salts such as sodium and potassium that govern fluid distribution and skeletal muscle contraction, rather than to a direct action of the compound on muscle tissue. The cramping itself is described as severe and painful, in the calves and shins, the biceps and the back during physical exertion.
Outside the trial record, skin findings appear in fewer accounts: a red rash across the upper thighs, reddened knuckles and markedly dry skin. Chest tightness is described as arising during exposure, sometimes on lying down to sleep, together with an abnormal sensation and pain on the left side, and one account attributes that pain directly to dehydration and electrolyte depletion rather than to any action of RAD140 on the heart.
In descriptions beyond the trials, two further complaints appear alongside these: profuse sweating and numbness in one leg. The electrolyte explanation offered within such accounts remains an interpretation, because none of them rests on a measurement of serum electrolytes, of blood pressure or of skin pathology.
Dose and length of exposure in the trial and the case reports
The trial administered 50 mg, 100 mg or 150 mg once daily and set 100 mg as the maximum tolerated dose. The published cases describe drug-induced liver injury after five weeks of exposure and again after 16 weeks. That structure of RAD140 doses says little about how harm relates to dose: the trial recorded severe events across the escalation, and it set the maximum tolerated dose at 100 mg because the level above it could not be sustained.
The cases complicate any reading by dose further. The injury in the 26-year-old man was characterised as idiosyncratic drug-induced liver injury, an unpredictable reaction that does not follow dose or duration the way a directly toxic effect would, so a low exposure cannot be read as a safe one. Neither the five-week nor the 16-week exposure came with any analysis of the product involved, which leaves the quantity actually reaching each patient unknown; the length of exposure is the only dimension these cases fix.
What the case reports recorded after exposure ended
In most of the published cases the drug-induced liver injury eased once exposure to the product ended. The 26-year-old man had a normalised liver function panel and no recurrence of symptoms at two-month follow-up. In the 22-year-old man, total bilirubin fell from a peak of 530 µmol/L to 188 µmol/L at one month, and the reviewing authors report liver enzymes normalising three to twelve months after the product was withdrawn. The 24-year-old man followed the same course: his total bilirubin peaked at 38.5 mg/dL, and both his symptoms and the drug-induced liver injury resolved after cessation of the agent.
The severe case broke the pattern. There, bilirubin went on rising despite withdrawal of the product and corticosteroid therapy, and the course ran on to plasmapheresis, pancreatitis and acute kidney injury. The contrast between the two courses is the most useful finding this small series offers on the kidneys: acute kidney injury appeared only where the drug-induced liver injury itself failed to settle after exposure ended.
What the products in the case reports contained
RAD-140 was not the only compound present in some of these reports. The supplement in the severe case also held andarine, and the splenic case followed recent exposure to MK-677 alongside RAD-140. No case in which two compounds were present can assign the injury to one of them, and the authors of the splenic case say as much when they call the contribution of either compound speculative.
Product labels are no more reliable. Australia’s Therapeutic Goods Administration (TGA) found, on testing unapproved SARM products, that they were significantly under-dosed: the packages named more than analysis found inside. None of the published cases reports an independent analysis of the product involved, a gap that leaves both the identity and the amount of each exposure uncertain. Laboratory work can do without that uncertainty, which is why the RAD-140 for sale in our shop comes with batch and purity data, as do the other SARMs for sale we supply in the UK for research.
RAD140 and the prostate in cell and animal studies
In prostate carcinoma cells grown in culture, RAD-140 showed androgenic activity in an androgen-responsive reporter gene assay, which couples a measurable signal to activation of the receptor under study. The same compounds produced weaker androgenic effects in a yeast androgen screen engineered to respond to androgen receptor ligands than in the prostate cells: the comparator compound GSK-2881078 gave a half-maximal effective concentration of 4.44 × 10⁻⁶ M in the yeast screen against 3.99 × 10⁻⁹ M in the prostate cells. When the three compounds were modelled in the ligand binding domain of the androgen receptor, slight differences in their binding modes appeared.
The animal work is older and answers a different question: the design and synthesis paper for RAD140 reported its potency and its oral bioavailability, the fraction of an orally administered dose that reaches the circulation intact, tested RAD140 in rats and monkeys across several preclinical models of anabolic androgen action, and reported binding affinities of 7 against 29 nM. Activity at an androgen-responsive gene in cultured prostate cells cannot stand as a statement about human prostate tissue, because neither the cell systems nor the animal models measured prostate volume, urinary symptoms or disease of the gland over time.
Limits of the evidence on kidneys, prostate and gut
The evidence on whether RAD-140 is bad for the kidneys, the prostate or the gut is thin in ways that bear on each organ question. Its event proportions come from 22 heavily pretreated women with advanced breast cancer and cannot be carried across to healthy men, and its PSA and SHBG movements were markers of receptor engagement, not prostate outcomes. Each published case beyond the trial describes a single patient, which establishes that an injury followed exposure but not how often such injuries occur.
Two further limits weaken the attribution of each injury to the compound. Some cases involved a second compound alongside RAD-140, and in the splenic rupture case the authors themselves judged the link speculative and found features raising the possibility of an underlying vascular malformation. The products are the other limit: no case included an analysis of the product involved, so the identity and quantity of each exposure remain unknown.
Joint pain, dry joints, tendon and ligament strain, headaches, dizziness, skeletal muscle cramps, rashes, chest tightness, lower back and kidney-area pain, and stomach upsets are described only outside the published trials and case reports, and no published study among this article’s sources has measured them.
No regulator has approved RAD140 for clinical use, and selective androgen receptor modulators stand on the WADA prohibited list for their myoanabolic effects.
Check what you remember
4 questions on this article; the right answer is marked.
The kidney injury came only after a severe cholestatic liver injury kept worsening despite withdrawal of the product and corticosteroids, alongside pancreatitis.
The trial enrolled only postmenopausal women and used PSA and SHBG as markers of androgen receptor engagement, measuring no prostate endpoint.
The spleen showed features raising the possibility of an underlying vascular malformation, and the authors called the role of RAD-140 and MK-677 speculative.
A 26-year-old man presented with nausea, vomiting, right upper quadrant pain and jaundice from acute drug-induced liver injury, with no other cause found.
Ailsa Gemmell · NHS Greater Glasgow and Clyde
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Laura Walker, PhD · Newcastle University · Last reviewed
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Related Posts
RAD 140 teenager: what a case report and animal data show
RAD 140 teenager evidence records harm: myopericarditis in a 16-year-old boy after his first dose, and raised frailty and mortality risk in mice.
RAD 140 lethargy: mood, sleep and what the evidence shows
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
RAD 140 side effects: what the trials and case reports show
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Does RAD 140 shrink balls? Hormone suppression and recovery
Does RAD 140 shrink balls: RAD140 can lower LH and FSH, and a case report recorded hormone levels that returned to normal once exposure ended.